Shanghai Haohai Biological Technology Co., Ltd. (688366.SS) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 688366.SS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.36% | 30.00% | Pass |
| Interest-bearing investments | 35.63% | 30.00% | Fail |
| Non-permissible income | 3.14% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.70% | 33.00% | Pass |
| Interest-bearing investments | 37.53% | 33.00% | Fail |
| Non-liquid assets | 58.44% | at least 20.00% | Pass |
| Non-permissible income | 3.14% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 37.53% | 33.33% | Fail |
| Accounts receivable | 41.56% | 33.33% | Fail |
| Non-permissible income | 3.14% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 37.53% | 33.33% | Fail |
| Accounts receivable | 41.56% | 50.00% | Pass |
| Non-permissible income | 3.14% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.75% | 33.00% | Pass |
| Cash + interest-bearing securities | 20.98% | 33.00% | Pass |
| Accounts receivable | 2.25% | 33.00% | Pass |
| Non-permissible income | 3.14% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.29% | 33.00% | Pass |
| Cash + interest-bearing securities | 18.43% | 49.00% | Pass |
| Accounts receivable | 1.98% | 49.00% | Pass |
| Non-permissible income | 3.14% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.29% | 33.33% | Pass |
| Cash + interest-bearing securities | 18.43% | 33.33% | Pass |
| Accounts receivable | 20.41% | 49.00% | Pass |
| Non-permissible income | 3.14% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 35.60 | NEUTRAL |
| Stochastic %K (14) | 10.82 | BUY |
| CCI (20) | -134.68 | BUY |
| Williams %R (14) | -89.18 | BUY |
| MACD (12,26,9) | -0.10 | SELL |
| ROC (10) | -4.75 | SELL |
| Momentum (10) | -1.44 | SELL |
| EMA (10) | 29.96 | SELL |
| SMA (10) | 29.99 | SELL |
| EMA (20) | 30.39 | SELL |
| SMA (20) | 30.48 | SELL |
| EMA (30) | 30.68 | SELL |
| SMA (30) | 31.08 | SELL |
| EMA (50) | 31.21 | SELL |
| SMA (50) | 31.22 | SELL |
| EMA (100) | 33.17 | SELL |
| SMA (100) | 32.54 | SELL |
| EMA (200) | 38.33 | SELL |
| SMA (200) | 38.08 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequency, and ultrasonic instruments. It also engages in the research and development of biological engineering and pharmaceutical products and related technology transfer activities, consulting, and other services; research, development, production, and sales of radio frequency instruments; cell technology and biochemical product technology research and development; computer, communication, and other electronic equipment manufacturing; instrument manufacturing; manufacture and sale of biological reagents, biological agents, and biological materials; medical-grade sodium hyaluronate bio-based skincare products; intraocular lens and related products; intraocular lens injectors and materials, equipment, chemical products, and accessories for contact lenses and artificial lenses; sale of ophthalmology products; and provision of other machines and accessories. In addition, the company is involved in property management; business management consulting; non-residential real estate leasing; provision of technical services, technology promotion, development and transfer, technical consulting and exchange; wholesale of cosmetics; import and export of goods; import and export of technology; and information technology consulting services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. The company was founded in 2007 and is headquartered in Shanghai, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
